關(guān)鍵字：腎小球腎炎,指南,新加坡衛(wèi)生部2007,Guideline Summary,Glomerulonephritis
簡(jiǎn)介：Guideline Title
Glomerulonephritis.
Bibliographic Source(s)
Singapore Ministry of Health. Glomerulonephritis. Singapore: Singapore Ministry of Health; 2007 Mar. 130 p. [234 references]
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: Singapore Ministry of Health. Glomerulonephritis. Singapore: Singapore Ministry of Health; 2001 Oct. 132 p.
The workgroup advises that these guidelines be scheduled for review five years after publication, or if new evidence appears that requires substantive changes to the recommendations.
FDA Warning/Regulatory Alert
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.
June 24, 2011 – Erythropoiesis-Stimulating Agents (ESAs) : The U.S. Food and Drug Administration (FDA) notified healthcare professionals that new, modified recommendations for more conservative dosing of Erythropoiesis-Stimulating Agents (ESAs) in patients with chronic kidney disease (CKD) have been approved to improve the safe use of these drugs. FDA has made these recommendations because of data showing increased risks of cardiovascular events with ESAs in this patient population.
June 8, 2011 – Zocor (simvastatin) : The U.S. Food and Drug Administration (FDA) notified healthcare professionals that it is recommending limiting the use of the highest approved dose of the cholesterol-lowering medication simvastatin (80 mg) because of increased risk of muscle damage. FDA is requiring changes to the simvastatin label to add new contraindications (should not be used with certain medications) and dose limitations for using simvastatin with certain medicines.
